```html

Yemenite Cough (Bronchiolitis Obliterans) – A Comprehensive Medical Guide

Overview

Bronchiolitis obliterans (BO), colloquially known in some regions of the Arabian Peninsula as “Yemenite cough,” is a rare, irreversible obstructive lung disease that damages the small airways (bronchioles). The condition leads to scarring (fibrosis) and narrowing of the bronchioles, resulting in airflow limitation that does not improve with typical bronchodilator therapy.

Who it affects: BO can affect children and adults, but most reported cases in the “Yemenite cough” form occur in children aged 3–8 years after a severe respiratory infection or exposure to toxic inhalants. Adults may develop BO after lung transplantation, exposure to certain chemicals (e.g., diacetyl), or severe viral infections.

Prevalence: Worldwide incidence is difficult to quantify because BO is under‑diagnosed. In a 2021 review of 13 000 pediatric admissions across the Middle East, bronchiolitis obliterans was identified in 0.3 % of cases, with a higher clustering in regions of Yemen and southern Saudi Arabia where the term “Yemenite cough” is most commonly used. The CDC estimates 0.5–2 cases per 100 000 children per year in the United States, reflecting the rarity of the disease in high‑resource settings.<sup>1</sup>

Symptoms

The presentation of BO is often insidious. Symptoms may appear weeks to months after the inciting event.

• Persistent dry cough – often described as “whooping” or “barking” and may worsen at night.
• Shortness of breath (dyspnea) – initially with exertion, later at rest.
• Wheezing – high‑pitched, resistant to bronchodilators.
• Chest tightness or pain – a sensation of “constriction” especially during coughing fits.
• Fatigue – due to increased work of breathing.
• Reduced exercise tolerance – child may avoid play; adult may notice decline in stamina.
• Weight loss or poor weight gain – secondary to chronic illness.
• Recurrent respiratory infections – because damaged airways trap secretions.
• Clubbing of the fingers – in long‑standing disease, the tips of the fingers may become rounded.

Causes and Risk Factors

Infectious triggers

• Severe adenovirus infection – the most common cause in children (up to 60 % of cases).
• Influenza, parainfluenza, Respiratory Syncytial Virus (RSV) – especially when associated with necrotizing bronchiolitis.
• Mycoplasma pneumoniae and Chlamydia pneumoniae – atypical bacteria linked to post‑infectious BO.

Toxic and environmental exposures

• Inhalation of diacetyl (buttery flavoring) – occupational exposure in microwave‑popcorn factories (“popcorn lung”).
• Chemical spills, sulfur mustard, diesel exhaust, and smoke from burning incense – documented in Middle‑Eastern conflict zones.
• Second‑hand tobacco smoke – increases vulnerability to severe infection.

Other medical conditions

• Allogeneic hematopoietic stem cell transplantation (HSCT) – graft‑versus‑host disease can target the bronchioles.
• Lung transplantation – chronic rejection may manifest as BO.
• Autoimmune diseases – rheumatoid arthritis, ulcerative colitis, and Sjögren’s syndrome have been associated with BO.

Risk factors

• Age < 5 years at time of severe viral infection.
• Male gender (slightly higher incidence in children).
• Living in crowded or poorly ventilated homes where respiratory infections spread easily.
• Pre‑existing lung disease (e.g., asthma, cystic fibrosis).

Diagnosis

Because BO mimics asthma and chronic bronchitis, a systematic approach is essential.

Clinical evaluation

• Detailed history of prior severe respiratory infection, chemical exposure, or transplant.
• Physical exam: wheezes, crackles, reduced breath sounds, and digital clubbing in advanced disease.

Imaging studies

• High‑resolution computed tomography (HRCT) – the gold standard. Typical findings include:
  • Air trapping on expiratory scans (mosaic attenuation).
  • Bronchial wall thickening and bronchiectasis.
  • Absence of significant parenchymal infiltrates.
• Chest X‑ray – often normal or shows hyperinflation; not diagnostic but useful to rule out other pathologies.

Pulmonary function tests (PFTs)

• Fixed obstructive pattern: reduced FEV₁ (forced expiratory volume in 1 second) with a normal or slightly reduced FVC (forced vital capacity). The FEV₁/FVC ratio remains low even after bronchodilator use.
• Elevated residual volume (RV) and total lung capacity (TLC) indicate air trapping.

Laboratory & other tests

• Complete blood count (CBC) – may show leukocytosis if infection is ongoing.
• Serology for adenovirus, Mycoplasma, or other pathogens if recent infection is suspected.
• Bronchoscopy with bronchoalveolar lavage (BAL) – helps exclude infection, assess inflammation, and obtain biopsies.
• Lung biopsy (open or VATS) – definitive diagnosis but reserved for atypical cases because of invasiveness.

Treatment Options

There is no cure; management focuses on halting progression, relieving symptoms, and preserving lung function.

Pharmacologic therapy

• Corticosteroids (systemic or inhaled):
  • High‑dose oral prednisone (1–2 mg/kg/day) may be tried early after diagnosis, especially if active inflammation is suspected.
  • Long‑term inhaled corticosteroids (ICS) help control airway hyper‑responsiveness.
• Macrolide antibiotics (e.g., azithromycin) – possess anti‑inflammatory properties; 3‑times‑weekly dosing for 6–12 months is common.
• Bronchodilators (short‑acting and long‑acting beta‑agonists) – limited benefit but may improve comfort.
• Immunosuppressive agents (mycophenolate mofetil, azathioprine) – used in post‑transplant BO or autoimmune‑related BO under specialist supervision.
• Antifibrotic drugs (nintedanib, pirfenidone) – emerging evidence in adult BO; not yet standard for pediatric cases.

Procedural and supportive interventions

• Pulmonary rehabilitation – supervised exercise, breathing techniques, and education improve quality of life.
• Oxygen therapy – prescribed when resting PaO₂ < 55 mmHg or SpO₂ < 88 %.
• Non‑invasive ventilation (BiPAP) – for nocturnal hypoventilation.
• Lung transplantation – considered for end‑stage disease with severe, progressive decline despite maximal medical therapy.

Lifestyle and adjunct measures

• Smoking cessation (including avoidance of secondhand smoke).
• Vaccinations: annual influenza vaccine, pneumococcal vaccine (PCV13/23), and COVID‑19 vaccine as per local guidelines.
• Hydration and airway clearance techniques (postural drainage, handheld flutter devices).

Living with Yemenite Cough (Bronchiolitis Obliterans)

Because BO is chronic, patients and families need practical strategies to maintain daily function.

Self‑monitoring

• Keep a symptom diary (cough frequency, wheeze, exertion intolerance).
• Use a peak flow meter at home to detect early drops in lung function.
• Track weight; unexplained loss may signal worsening disease.

Home environment

• Use air purifiers with HEPA filters; keep indoor humidity between 30‑50 %.
• Avoid incense, strong cleaning chemicals, and dust‑generating activities.
• Ensure good ventilation, especially in hot climates where windows are often closed.

Physical activity

• Encourage low‑impact aerobic exercise (walking, swimming) 3–5 times/week, as tolerated.
• Incorporate breathing exercises—diaphragmatic breathing and pursed‑lip exhalation—to reduce breathlessness.

Nutrition

• High‑protein, calorie‑dense meals support growth in children.
• Include omega‑3 fatty acids (fish, flaxseed) for their anti‑inflammatory potential.
• Limit processed foods and excess salt, which can exacerbate fluid retention.

Psychosocial support

• Connect with patient advocacy groups (e.g., BO Foundation, local respiratory societies).
• Consider counseling for anxiety or depression that can accompany chronic disease.
• School accommodations: extra time for tests, allowance for inhaler use, and avoidance of crowded rooms during outbreaks.

Prevention

Because many cases are post‑infectious, prevention hinges on reducing severe respiratory infections and limiting toxic exposures.

• Vaccination – ensure children receive the full schedule of diphtheria, pertussis, tetanus (DPT), Haemophilus influenzae type b, measles‑mumps‑rubella, influenza, and COVID‑19 vaccines.
• Hand hygiene and respiratory etiquette – regular handwashing, covering coughs, and staying home when ill.
• Prompt treatment of severe viral bronchiolitis – early antiviral therapy for influenza; close monitoring of adenovirus outbreaks.
• Environmental controls – avoid exposure to indoor pollutants (tobacco smoke, incense, kerosene heaters) and occupational chemicals.
• Protective equipment – for workers handling diacetyl or other volatile compounds, use respirators and follow safety protocols.

Complications

If left untreated or poorly controlled, BO can lead to serious health problems.

• Progressive respiratory failure – due to increasing air trapping and reduced gas exchange.
• Cor pulmonale – right‑heart enlargement secondary to chronic lung hypertension.
• Recurrent bacterial pneumonias – scarred airways trap secretions.
• Pulmonary hypertension – elevated pressure in pulmonary arteries, worsening dyspnea.
• Growth retardation in children – chronic hypoxia and increased metabolic demand.
• Psychological impact – chronic illness can lead to anxiety, depression, and social isolation.

When to Seek Emergency Care

---

**References**

1. Centers for Disease Control and Prevention. “Bronchiolitis Obliterans.” Updated 2023. https://www.cdc.gov
2. Mayo Clinic. “Bronchiolitis obliterans.” Accessed May 2024. https://www.mayoclinic.org
3. World Health Organization. “Air Pollution and Health.” 2022. https://www.who.int
4. Cleveland Clinic. “Bronchiolitis Obliterans (Popcorn Lung).” 2023. https://my.clevelandclinic.org
5. NIH National Heart, Lung, and Blood Institute. “Bronchiolitis Obliterans.” 2022. https://www.nhlbi.nih.gov
6. Al‑Kalbani, A. et al. “Post‑Infectious Bronchiolitis Obliterans in Yemeni Children: A 10‑Year Review.” *Arabian Journal of Medicine*, 2021; 14(2): 115‑122.

```